Drug Discovery World
FEBRUARY 28, 2023
Interestingly, at least 80% of all rare diseases originate from monogenic mutations, meaning that they arise from mutations in a single gene 4. Therefore, the risk for off-target insertional mutagenesis is greatly reduced. In addition, it may be easier to target the therapeutic molecule to the correct cell or tissue.
pharmaphorum
APRIL 5, 2022
The technique uses artificial intelligence (AI) to analyse protein data harvested from tumour cells, using an algorithm trained by looking at changes to 52 proteins when they are exposed to a panel of targeted anticancer drugs. The post AI test could predict best cancer therapies for patients appeared first on.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
MARCH 7, 2024
The company’s ResolveOME multiomic workflow provides a comprehensive multiomic analysis of breast cancer through the use of exome hybrid capture alongside a single-cell workflow for single-cell resolution of single nucleotide variants (SNVs), copy number alterations and gene expression signatures, coupled with a targeted protein panel.
Drug Discovery World
JUNE 14, 2023
BCA members also operate the BCA Advanced Therapies Network which is a diverse, fully integrated portfolio of blood, cell, gene and tissue materials that support the development and delivery of advanced therapies. One example we are following with anticipation are the two FDA approvals for the first gene therapies for sickle cell disease.
Drug Discovery World
APRIL 21, 2023
SLAS Student Poster Award The SLAS Student Poster Award recognises innovative research by students, graduate students, post- doctoral associates and junior faculty (less than four years in first academic appointment) who are chosen to present a poster during SLAS Europe 2023.
Expert insights. Personalized for you.
52 
Let's personalize your content